501 related articles for article (PubMed ID: 14660715)
1. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma.
Yamamoto Y; Nishiyama Y; Monden T; Matsumura Y; Satoh K; Ohkawa M
J Nucl Med; 2003 Dec; 44(12):1905-10. PubMed ID: 14660715
[TBL] [Abstract][Full Text] [Related]
2. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.
Chen L; Luo Q; Shen Y; Yu Y; Yuan Z; Lu H; Zhu R
J Nucl Med; 2008 Dec; 49(12):1952-7. PubMed ID: 18997044
[TBL] [Abstract][Full Text] [Related]
3. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging.
Spanu A; Solinas ME; Chessa F; Sanna D; Nuvoli S; Madeddu G
J Nucl Med; 2009 Feb; 50(2):184-90. PubMed ID: 19164225
[TBL] [Abstract][Full Text] [Related]
4. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.
Tharp K; Israel O; Hausmann J; Bettman L; Martin WH; Daitzchman M; Sandler MP; Delbeke D
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1435-42. PubMed ID: 15221294
[TBL] [Abstract][Full Text] [Related]
5. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma.
Wong KK; Zarzhevsky N; Cahill JM; Frey KA; Avram AM
AJR Am J Roentgenol; 2008 Dec; 191(6):1785-94. PubMed ID: 19020251
[TBL] [Abstract][Full Text] [Related]
6. The value of simultaneous co-registration of 99mTc- MDP and 131Iodine in metastatic differentiated thyroid carcinoma.
Kotb MH; Omar W; El-Maghraby T; El-Bedwihy M; El-Tawdy M; Mustafa H; Al-Nahhas A
Nucl Med Rev Cent East Eur; 2007; 10(2):98-105. PubMed ID: 18228214
[TBL] [Abstract][Full Text] [Related]
7. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.
Wang H; Fu HL; Li JN; Zou RJ; Gu ZH; Wu JC
Clin Imaging; 2009; 33(1):49-54. PubMed ID: 19135930
[TBL] [Abstract][Full Text] [Related]
8. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384
[TBL] [Abstract][Full Text] [Related]
9. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT.
Wong KK; Sisson JC; Koral KF; Frey KA; Avram AM
AJR Am J Roentgenol; 2010 Sep; 195(3):730-6. PubMed ID: 20729453
[TBL] [Abstract][Full Text] [Related]
10. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
11. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne.
Pérault C; Schvartz C; Wampach H; Liehn JC; Delisle MJ
J Nucl Med; 1997 Aug; 38(8):1234-42. PubMed ID: 9255157
[TBL] [Abstract][Full Text] [Related]
12. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
13. [Fusion of SPECT with computed tomography or magnetic resonance for the interpretation of abnormal tracer uptake].
Aqueveque A C; González E P; Gutiérrez B D; Jaimovich F R; Díaz P JC; Csendes G P; Orellana P P; Lavados M H; Alliende G I; Araya L S
Rev Med Chil; 2007 Jun; 135(6):725-34. PubMed ID: 17728898
[TBL] [Abstract][Full Text] [Related]
14. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
15. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
16. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
17. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
18. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study.
Ota N; Kato K; Iwano S; Ito S; Abe S; Fujita N; Yamashiro K; Yamamoto S; Naganawa S
Br J Radiol; 2014 Feb; 87(1034):20130444. PubMed ID: 24297809
[TBL] [Abstract][Full Text] [Related]
20. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation.
Schmidt D; Szikszai A; Linke R; Bautz W; Kuwert T
J Nucl Med; 2009 Jan; 50(1):18-23. PubMed ID: 19091884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
